Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lepu Biopharma CoHKSE:02157 -3.04%45 PE Ratio (TTM) is 22.93 as of Aug. 24, 2026, which is 18% below its 10-year median of 28.01. GuruFocus rates HKSE:02157 with a GF Score™ of 45/100 and a GF Value™ of HK$16.73 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 282 Biotechnology companies, Lepu Biopharma Co ranks better than 55.67% on this metric.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-08-24), Lepu Biopharma Co's share price is
HK$3.83.
Lepu Biopharma Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.17. Therefore, Lepu Biopharma Co's PE Ratio (TTM) for today is 22.93.
Good Sign:
Lepu Biopharma Co Ltd stock PE Ratio (=23.8) is close to 1-year low of 21.57.
The historical rank and industry rank for Lepu Biopharma Co's PE Ratio (TTM) or its related term are showing as below:
HKSE:02157'
s PE Ratio (TTM) Range Over the Past 10 Years
Min: 21.57 Med: 28.01 Max: 38.37
Current: 22.93
During the past 7 years, the highest PE Ratio (TTM) of Lepu Biopharma Co was 38.37. The lowest was 21.57. And the median was 28.01.
HKSE:02157's PE Ratio (TTM) is ranked better than 55.67% of 282
companies
in the Biotechnology industry
Industry Median: 27.41
vs HKSE:02157: 22.93
During the past 3 years, the average EPS without NRIGrowth Rate was 67.60% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 44.50% per year.
During the past 7 years, Lepu Biopharma Co's highest 3-Year average EPS without NRI Growth Rate was 67.60% per year. The lowest was -16.10% per year. And the median was 29.00% per year.
Lepu Biopharma Co's EPS (Basic) for the
six
months ended in Dec. 2025 was HK$0.14.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.17.
Lepu Biopharma Co (HKSE:02157) PE Ratio (TTM) Explanation
The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.
If a company loses money, the PE Ratio (TTM) becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.
Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .
PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).
Lepu Biopharma Co PE Ratio (TTM) Related Terms
Lepu Biopharma Co PE Ratio (TTM) Historical Data
* Premium members only.
The historical data trend for Lepu Biopharma Co's PE Ratio (TTM) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02157 vs VRTX, REGN, RVMD: PE Ratio (TTM) Comparison
For the Biotechnology subindustry, Lepu Biopharma Co's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lepu Biopharma Co PE Ratio (TTM) vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lepu Biopharma Co's PE Ratio (TTM) distribution charts can be found below:
* The bar in red indicates where Lepu Biopharma Co's PE Ratio (TTM) falls into.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.
Lepu Biopharma Co's Share Price of today is HK$3.83.
For company reported semi-annually, Lepu Biopharma Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.17.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
Lepu Biopharma Co (HKSE:02157) has a PE Ratio (TTM) of 22.93 as of Aug. 24, 2026. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Lepu Biopharma Co and its competitors. This is 18% below median its historical median of 28.01. Over the past decade, Lepu Biopharma Co's PE Ratio (TTM) has ranged from 21.57 to 38.37. According to the industry distribution chart, Lepu Biopharma Co ranks #125 out of 282 companies in the Biotechnology industry, placing it in the top 44.3%.
Is Lepu Biopharma Co's PE Ratio (TTM) too high?
Lepu Biopharma Co's current PE Ratio (TTM) of 22.93 is 18% below median its 10-year median of 28.01. Over the past 10 years, this metric has ranged from a low of 21.57 to a high of 38.37. The Biotechnology industry median PE Ratio (TTM) is 27.41. Lepu Biopharma Co's value of 22.93 is 16.3% below this industry median. Based on the distribution chart, Lepu Biopharma Co ranks #125 out of 282 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Lepu Biopharma Co has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lepu Biopharma Co's PE Ratio (TTM) compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lepu Biopharma Co ranks #125 out of 282 companies for PE Ratio (TTM). This puts Lepu Biopharma Co in the upper half of its industry. The industry median PE Ratio (TTM) is 27.41. Lepu Biopharma Co's value of 22.93 is 16.3% below this benchmark. Historically, Lepu Biopharma Co's own PE Ratio (TTM) has ranged from 21.57 to 38.37 over the past decade. While the company's 10-year median is 28.01 vs. the industry median of 27.41, Lepu Biopharma Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio (TTM) for a Biotechnology company?
The median PE Ratio (TTM) among Biotechnology companies is 27.41, based on 282 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio (TTM) significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lepu Biopharma Co's current PE Ratio (TTM) of 22.93 is 16.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio (TTM) mean?
A high PE Ratio (TTM) can signal that a stock is expensive relative to its fundamentals. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Lepu Biopharma Co and its competitors. For the Biotechnology industry, the median PE Ratio (TTM) is 27.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lepu Biopharma Co's current PE Ratio (TTM) is 22.93, which is 18% below median its own 10-year median of 28.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lepu Biopharma Co stock overvalued right now?
Based on GuruFocus' analysis, Lepu Biopharma Co (HKSE:02157) is currently considered Possible Value Trap. The stock's GF Value™ is HK$16.73, compared to a current price of HK$3.83 — trading 77.1% below its estimated fair value. The current PE Ratio (TTM) is 22.93, which is 18% below median its 10-year median of 28.01 and 16.3% below the Biotechnology industry median of 27.41. Lepu Biopharma Co's overall GF Score™ is 45/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio (TTM) calculated?
PE Ratio (TTM) is calculated from a company's financial statements. For Lepu Biopharma Co (HKSE:02157), the current PE Ratio (TTM) is 22.93 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lepu Biopharma Co (HKSE:02157) Overvalued in 2026?
Based on GuruFocus' analysis, Lepu Biopharma Co stock appears to be undervalued.
The current stock price of HK$3.83 is trading 77.1% below its estimated GF Value™ of HK$16.73.
GuruFocus considers Lepu Biopharma Co to be Possible Value Trap.
Key valuation signals for HKSE:02157:
PE Ratio (TTM): 22.93 (18% below median its 10-year median of 28.01)
GF Value™: HK$16.73 vs. price of HK$3.83 (77.1% below fair value)
Industry Position: 16.3% below the Biotechnology median (#125 of 282)
No single metric tells the full story. See the HKSE:02157 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lepu Biopharma Co Ltd is focused on discovering, developing, and commercializing drug candidates in anti-tumor targeted therapy and oncology immunotherapy. Its commercial products include Puyouheng (Pucotenlimab Injection) and Meiyouheng (Becotatug Vedotin Injection). In addition, two other products, CMG901 and MRG007, have also been licensed out through its business development activities. Additionally, the company has several clinical-stage drug candidates and clinical-stage combination therapies of candidates, which are being developed as targeted therapeutics and immunotherapeutics. The various drug candidates in its pipeline include MRG003, MRG002, MRG004A, CG0070, MRG001, and MRG006A, among others. Geographically, the company generates maximum revenue from the Chinese mainland.
45GF Score
Get the complete analysis for HKSE:02157
PE Ratio (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02157 has been successfully added to your 
